KR870000920A - 9-데옥소-11-데옥시-9,11-[이미노[2-(2-메톡시에톡시) 에틸리덴]-옥시]-(9s)-에리트로마이신을 함유하는 경구투여용 고형 약제학적 제제의 제조방법 - Google Patents
9-데옥소-11-데옥시-9,11-[이미노[2-(2-메톡시에톡시) 에틸리덴]-옥시]-(9s)-에리트로마이신을 함유하는 경구투여용 고형 약제학적 제제의 제조방법 Download PDFInfo
- Publication number
- KR870000920A KR870000920A KR1019860005492A KR860005492A KR870000920A KR 870000920 A KR870000920 A KR 870000920A KR 1019860005492 A KR1019860005492 A KR 1019860005492A KR 860005492 A KR860005492 A KR 860005492A KR 870000920 A KR870000920 A KR 870000920A
- Authority
- KR
- South Korea
- Prior art keywords
- active substance
- basic
- lacquer
- mixture
- coated
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 9
- -1 2-methoxyethoxy Chemical group 0.000 title claims 3
- 239000007787 solid Substances 0.000 title claims 3
- 229960003276 erythromycin Drugs 0.000 title claims 2
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 title claims 2
- 125000001841 imino group Chemical group [H]N=* 0.000 title claims 2
- 238000002360 preparation method Methods 0.000 title claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 12
- 239000013543 active substance Substances 0.000 claims 11
- 239000004922 lacquer Substances 0.000 claims 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 4
- 239000008187 granular material Substances 0.000 claims 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- 239000008188 pellet Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 2
- 239000012798 spherical particle Substances 0.000 claims 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- RJZNFXWQRHAVBP-UHFFFAOYSA-I aluminum;magnesium;pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Al+3] RJZNFXWQRHAVBP-UHFFFAOYSA-I 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims 1
- 239000000920 calcium hydroxide Substances 0.000 claims 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000004051 gastric juice Anatomy 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- 239000006166 lysate Substances 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 claims 1
- 239000002370 magnesium bicarbonate Substances 0.000 claims 1
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 claims 1
- 235000014824 magnesium bicarbonate Nutrition 0.000 claims 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims 1
- 239000001095 magnesium carbonate Substances 0.000 claims 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims 1
- 239000000347 magnesium hydroxide Substances 0.000 claims 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims 1
- 239000000395 magnesium oxide Substances 0.000 claims 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000000155 melt Substances 0.000 claims 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229960003975 potassium Drugs 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011736 potassium bicarbonate Substances 0.000 claims 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims 1
- 235000015497 potassium bicarbonate Nutrition 0.000 claims 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 229940083608 sodium hydroxide Drugs 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 229940001496 tribasic sodium phosphate Drugs 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
내용 없음.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 부형제를 함유하지 않은 정제와 비교하여, pH6의 인공장액 중에서 실시예 1에 따라 제조된 정제의 용해프로필(profile)을 나타내는 그래프.
Claims (9)
- 활성물질을, 활성물질 1몰에 대해 염기성 부형제 2g-당량 이상의 비로, 염기성 부형제와 완전히 혼합한후, a) 이 완전 혼합물을 추가의 부형제를 첨가한 후에 과립화시키고, 압축시켜 정제를 제조하거나, b) 이 완전 혼합물을 점착제 물질과 결합시켜 펠렛화 시키거나, c) 이 완전 혼합물을 압축시킨 다음 과립으로 분쇄하여 목적하는 크기의 과립 분획을 선별하거나, d) 이 완전 혼합물을 용융물 중에 현탁시키고 용융물을 냉각탑에서 분무하여 특정 직경의 구형 입자를 제조하고, 이렇게 하여 수득된 제제를 이어서 pH5.5 내지 6.8의 범위에서 활성물질을 방출하는 위액-저항성 락커의 피복물로 피복시키고, 원하는 경우 단계 c) 또는 d)에 따라 수득된 입자를 현탁매질 중에 현탁시켜 시럽제를 제조함을 특징으로 하여, 활성물질로 9-데옥소-11-데옥시-9,11-[이미노-[2-(2-메톡시에톡시)에틸리덴]-옥시]-(9s)-에리트로마이신을 함유하는 경구투여용 고형 약제학적 제제를 제조하는 방법.
- 제1항에 있어서, 경구 투여용 약제학적 제제가 붕해제를 함유함을 특징으로 하는 방법.
- 제1항 또는 2항에 있어서, 활성물질과 염기성 부형제와의 완전 혼합물을 통상적 부형제와 함께 압축시켜 정제를 제조하고 이정재를 pH5.5 내지 6.8의 범위에서 활성물질을 방출하는 락커로 피복시킴을 특징으로 하는 방법.
- 제1항 또는 2항에 있어서, 활성물질과 염기성 부형제와의 완전 혼합물을 펠렛 형태로 제조하고 이 펠렛을 pH5.5 내지 6.8의 범위에서 활성물질을 방출하는 락커로 피복시킴을 특징으로 하는 방법.
- 제1항 또는 2항에 있어서, 활성물질과 염기성 부형재와의 완전 혼합물을 과립형태로 제조하고, 이 과립을 pH 5.5 내지 6.8의 범위에서 활성 물질을 특징으로 하는 방법.
- 제1항 또는 2항에 있어서, 활성물질과 염기성부형재의 완전 혼합물을, pH5.5내지 6.8의 범위에서 활성물질을 방출하는 락커로 피복시킨 분무-경화된 구형 입자의 형태로 제조함을 특징으로하는 방법.
- 제1항 내지 6항 중 어느 한 항에서, 경구투여용 고형 약제학적 제제가 pH 6.0 내지 6.4의 범위에서 활성물질을 방출하는 락커로 피복됨을 특징으로 하는 방법.
- 제1항 내지 7항 중 어느 한 항에서, 사용된 염기성 부형제가 산화마그네슘, 수산화 마그네슘, 탄산마그네슘, 탄산수소 마그네슘, 수산화칼슘, 탄산칼슘, 수산화 알루미늄 마그네슘, 마그네슘 알루미네이트, 탄산나트륨, 탄산수소 나트륨, 탄산칼륨, 탄산수소칼륨, 수산화나트륨 수산화칼륨 또는 제 3 인산 나트륨이고 이는 활성물질 1g-몰에 대해 염기성 부형제 2내지 50g-당량의 비로 사용되며, 제제는 피복물이 2시간까지의 기간동안 위액에 대해 저항성이 유지되도록 하는 양의, 히드록시프로필메틸 셀룰로오즈 프탈레이트, 메타크릴산과 메틸메타크릴레이트의 공중합체, 셀룰로오즈 아세테이트 프탈레이트 또는 이들 화합물의 혼합물로 이루어진 락커로 피복시키며, 활성물질과 염기성 부형제와의 혼합물이 또한 추가의 보조제를 함유함을 특징으로 하는 방법.
- 제8항에 있어서, 염기성부형제로서 상이한 염기성 부형제들의 혼합물이 사용됨을 특징으로하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19853524572 DE3524572A1 (de) | 1985-07-10 | 1985-07-10 | Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung |
| DEP3524572.7 | 1985-07-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR870000920A true KR870000920A (ko) | 1987-03-10 |
| KR930010586B1 KR930010586B1 (ko) | 1993-10-30 |
Family
ID=6275375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019860005492A KR930010586B1 (ko) | 1985-07-10 | 1986-07-08 | 9-데옥소-11-데옥시-9,11-[이미노[2-(2-메톡시에톡시)에틸리덴]옥시]-(9s)-에리트로마이신을 함유하는 경구투여용 고형 약제학적 제제의 제조방법 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US4755385A (ko) |
| EP (1) | EP0208971B1 (ko) |
| JP (1) | JPH0688905B2 (ko) |
| KR (1) | KR930010586B1 (ko) |
| AT (1) | ATE63819T1 (ko) |
| AU (1) | AU586262B2 (ko) |
| CA (1) | CA1271138A (ko) |
| DD (1) | DD248057A5 (ko) |
| DE (2) | DE3524572A1 (ko) |
| DK (1) | DK165670C (ko) |
| ES (1) | ES2000269A6 (ko) |
| FI (1) | FI85649C (ko) |
| GR (1) | GR861762B (ko) |
| HK (1) | HK79791A (ko) |
| HU (1) | HU195730B (ko) |
| IE (1) | IE58951B1 (ko) |
| IL (1) | IL79375A (ko) |
| MX (1) | MX9202785A (ko) |
| NL (1) | NL970004I2 (ko) |
| NO (1) | NO175351C (ko) |
| NZ (1) | NZ216794A (ko) |
| PH (1) | PH26147A (ko) |
| PT (1) | PT82949B (ko) |
| SG (1) | SG72191G (ko) |
| ZA (1) | ZA865105B (ko) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8628359D0 (en) * | 1986-11-27 | 1986-12-31 | Zyma Sa | Galenical formulation |
| US4945080A (en) * | 1987-05-26 | 1990-07-31 | Eli Lilly And Company | Dirithromycin metabolite |
| US5030447A (en) * | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
| US5180589A (en) * | 1988-03-31 | 1993-01-19 | E. R. Squibb & Sons, Inc. | Pravastatin pharmaceuatical compositions having good stability |
| IT1230576B (it) * | 1988-10-20 | 1991-10-28 | Angeli Inst Spa | Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon |
| US5556839A (en) * | 1991-04-29 | 1996-09-17 | Eli Lilly And Company | Form II Dirithromycin |
| ZA922777B (en) * | 1991-04-29 | 1993-10-15 | Lilly Co Eli | Pharmaceutical formulation containing dirithromycin |
| IT1250701B (it) * | 1991-07-24 | 1995-04-21 | Angelini Francesco Ist Ricerca | Composizione farmaceutica solida per uso orale a base di dapiprazolo |
| HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
| IT1256386B (it) * | 1992-11-13 | 1995-12-04 | Luigi Boltri | Composizioni farmaceutiche comprendenti un farmaco,una sostanza polimerica reticolata,un olio ed un agente tensioattivo |
| MX9603480A (es) * | 1994-02-16 | 1997-12-31 | Abbott Lab | Procedimiento para preparar formulaciones farmaceuticas en particulas finas. |
| US6068859A (en) * | 1994-05-06 | 2000-05-30 | Pfizer Inc. | Controlled-release dosage forms of Azithromycin |
| US6066342A (en) * | 1995-12-22 | 2000-05-23 | Tamer International, Ltd. | Antacid composition |
| US5853787A (en) * | 1995-12-22 | 1998-12-29 | Tamer International | Method for reducing coffee acidity |
| US6045843A (en) * | 1995-12-22 | 2000-04-04 | Tamer International, Inc. | Acid-reduced, whole bean coffee process |
| US6495180B1 (en) | 1995-12-22 | 2002-12-17 | Tamer International, Ltd. | Acid reduced whole bean coffee and process |
| BE1011045A3 (fr) * | 1997-03-14 | 1999-04-06 | Ucb Sa | Compositions pharmaceutiques pour la liberation controlee de substances actives. |
| US20020018754A1 (en) * | 1999-03-15 | 2002-02-14 | Paul Albert Sagel | Shapes for tooth whitening strips |
| US6582708B1 (en) | 2000-06-28 | 2003-06-24 | The Procter & Gamble Company | Tooth whitening substance |
| US6096328A (en) | 1997-06-06 | 2000-08-01 | The Procter & Gamble Company | Delivery system for an oral care substance using a strip of material having low flexural stiffness |
| DE19925710C2 (de) * | 1999-06-07 | 2002-10-10 | Byk Gulden Lomberg Chem Fab | Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer |
| WO2000074654A1 (en) * | 1999-06-07 | 2000-12-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Novel preparation and administration form comprising an acid-labile active compound |
| BR0012145A (pt) | 1999-07-02 | 2002-04-30 | Procter & Gamble | Sistema de liberação de composições de tratamento oral, compreendendo resinas de organossiloxano usando uma fita de apoio removìvel |
| EP1118321A1 (fr) * | 2000-01-14 | 2001-07-25 | Ucb, S.A. | Compositions pharmaceutiques solides pour la libération contrôlée de substances actives |
| US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
| US6565882B2 (en) | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
| US6242003B1 (en) | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
| JP2004501173A (ja) * | 2000-06-28 | 2004-01-15 | ザ、プロクター、エンド、ギャンブル、カンパニー | ペルオキシド活性物質の安定性を高める構造体及び組成物 |
| US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
| US6541014B2 (en) | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
| US20060127474A1 (en) * | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
| US6949240B2 (en) * | 2002-05-23 | 2005-09-27 | The Procter & Gamble Company | Tooth whitening products |
| US8524200B2 (en) | 2002-09-11 | 2013-09-03 | The Procter & Gamble Company | Tooth whitening products |
| AU2004258949B2 (en) | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| JP2006528190A (ja) | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
| WO2005009364A2 (en) | 2003-07-21 | 2005-02-03 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
| JP2007502296A (ja) | 2003-08-11 | 2007-02-08 | アドバンシス ファーマスーティカル コーポレイション | ロバストペレット |
| JP2007502294A (ja) | 2003-08-12 | 2007-02-08 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
| JP5686494B2 (ja) | 2003-08-29 | 2015-03-18 | シオノギ インコーポレイテッド | 抗生物質製剤、その使用法及び作成方法 |
| AU2004273830B2 (en) | 2003-09-15 | 2011-03-24 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| AU2005269981A1 (en) | 2004-07-02 | 2006-02-09 | Bonck, John A | Tablet for pulsed delivery |
| EP2559430B1 (en) | 2005-03-22 | 2015-06-24 | Losan Pharma GmbH | Solubilized Ibuprofen |
| WO2007013794A1 (en) * | 2005-07-29 | 2007-02-01 | Stichting Groningen Centre For Drug Research | Ph-controlled pulsatile delivery system, methods for preparation and use thereof |
| CN101309674A (zh) | 2005-11-17 | 2008-11-19 | 诺瓦提斯公司 | 药物组合物 |
| US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
| US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
| JPWO2007126039A1 (ja) * | 2006-04-28 | 2009-09-10 | 塩野義製薬株式会社 | マクロライド系抗生物質の被覆製剤 |
| US8299052B2 (en) * | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
| EP2908798B1 (en) | 2012-10-17 | 2018-08-22 | The Procter and Gamble Company | Strip for the delivery of an oral care active and methods for applying oral care actives |
| GB2533593A (en) * | 2014-12-22 | 2016-06-29 | Parkside Flexibles (Europe) Ltd | Package |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3081233A (en) * | 1960-08-08 | 1963-03-12 | Upjohn Co | Enteric-coated pilules |
| US4000254A (en) * | 1966-04-25 | 1976-12-28 | Schmid Laboratories, Inc. | Fungimycin compositions |
| US3784683A (en) * | 1971-03-29 | 1974-01-08 | Abbott Lab | Tablet preparation |
| US3865935A (en) * | 1972-08-10 | 1975-02-11 | Abbott Lab | Tableting of erythromycin base |
| US3891755A (en) * | 1973-07-11 | 1975-06-24 | Abbott Lab | Dosage formulation for erythromycin cetyl sulfate |
| AT342770B (de) * | 1975-04-07 | 1978-04-25 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer erythromycinderivate |
| US4127647A (en) * | 1975-04-08 | 1978-11-28 | Meiji Seika Kaisha, Ltd. | Process for preparation of stable amorphous macrolide antibiotic solids |
| JPS5840529B2 (ja) * | 1975-09-29 | 1983-09-06 | 明治製菓株式会社 | ケイコウヨウセイザイノセイホウ |
| US4289751A (en) * | 1979-06-29 | 1981-09-15 | Merck & Co., Inc. | Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof |
| US4340582A (en) * | 1981-01-15 | 1982-07-20 | Abbott Laboratories | Erythromycin base tablets |
| JPS59104326A (ja) * | 1982-12-04 | 1984-06-16 | Toyo Jozo Co Ltd | マクロライド抗生物質の安定な経口用製剤および安定化法 |
-
1985
- 1985-07-10 DE DE19853524572 patent/DE3524572A1/de not_active Withdrawn
-
1986
- 1986-06-27 DE DE8686108791T patent/DE3679463D1/de not_active Expired - Lifetime
- 1986-06-27 EP EP86108791A patent/EP0208971B1/de not_active Expired - Lifetime
- 1986-06-27 AT AT86108791T patent/ATE63819T1/de active
- 1986-07-07 GR GR861762A patent/GR861762B/el unknown
- 1986-07-08 KR KR1019860005492A patent/KR930010586B1/ko not_active IP Right Cessation
- 1986-07-08 DD DD86292273A patent/DD248057A5/de not_active IP Right Cessation
- 1986-07-08 CA CA000513268A patent/CA1271138A/en not_active Expired - Lifetime
- 1986-07-08 DK DK324786A patent/DK165670C/da not_active IP Right Cessation
- 1986-07-08 US US06/882,999 patent/US4755385A/en not_active Expired - Lifetime
- 1986-07-09 PT PT82949A patent/PT82949B/pt unknown
- 1986-07-09 IE IE184286A patent/IE58951B1/en not_active IP Right Cessation
- 1986-07-09 IL IL79375A patent/IL79375A/xx not_active IP Right Cessation
- 1986-07-09 NZ NZ216794A patent/NZ216794A/xx unknown
- 1986-07-09 ES ES8600197A patent/ES2000269A6/es not_active Expired
- 1986-07-09 AU AU59876/86A patent/AU586262B2/en not_active Expired
- 1986-07-09 NO NO862772A patent/NO175351C/no not_active IP Right Cessation
- 1986-07-09 JP JP61159913A patent/JPH0688905B2/ja not_active Expired - Lifetime
- 1986-07-09 ZA ZA865105A patent/ZA865105B/xx unknown
- 1986-07-09 HU HU862853A patent/HU195730B/hu unknown
- 1986-07-10 FI FI862898A patent/FI85649C/fi not_active IP Right Cessation
- 1986-07-11 PH PH34006A patent/PH26147A/en unknown
-
1991
- 1991-08-26 SG SG721/91A patent/SG72191G/en unknown
- 1991-10-10 HK HK797/91A patent/HK79791A/xx not_active IP Right Cessation
-
1992
- 1992-06-11 MX MX9202785A patent/MX9202785A/es unknown
-
1997
- 1997-01-31 NL NL970004C patent/NL970004I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR870000920A (ko) | 9-데옥소-11-데옥시-9,11-[이미노[2-(2-메톡시에톡시) 에틸리덴]-옥시]-(9s)-에리트로마이신을 함유하는 경구투여용 고형 약제학적 제제의 제조방법 | |
| CN1230153C (zh) | 具有增强崩解性的薄膜包衣片组合物 | |
| ES2226886T3 (es) | Forma de administracion de accion retardada que contiene sacarinato de tramadol. | |
| US6773720B1 (en) | Mesalazine controlled release oral pharmaceutical compositions | |
| US5283065A (en) | Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form | |
| AU638012B2 (en) | Sustained-release oral drug dosage form | |
| AU563725B2 (en) | Oral controlled release multiple unit formulation | |
| EP0255404B1 (en) | Sustained release ibuprofen formulation | |
| WO1998009597A2 (en) | Cushioning beads and tablet comprising the same capable of forming a suspension | |
| GB2101485A (en) | Delayed-release pharmaceutical compositions of bromhexine | |
| SE8603247L (sv) | Granulerad form med fordrojd frigoring av farmaceutiskt aktiva substanser | |
| ZA200402460B (en) | Galenic microparticulate oral formulation | |
| WO1991006281A1 (en) | Gastric preparation | |
| PT93029A (pt) | Processo para a preparacao de uma composicao contendo acido 5-(2,5- dimetilfenoxi)-2,2-dimetil-pentanoico (gemfibrozilo) de libertacao modificada | |
| SU1218919A3 (ru) | Способ получени цефалексина продленного действи дл перорального применени | |
| JPS62120315A (ja) | 経口投与型徐放性錠剤の製造方法 | |
| WO1989008448A1 (en) | Enteric coated spheroidal granules | |
| AR036797A1 (es) | Un metodo para preparar una composicion farmaceutica que comprende acido 5-aminosalicilico para utilizar en el tratamiento de colitis ulcerosa y enfermedades de crohn | |
| SU1478993A3 (ru) | Способ получени микрогранул | |
| GB2190287A (en) | Oral ketoprofen formulation | |
| EP1000614A1 (en) | Sucralfate-containing composition and process for the preparation thereof | |
| JPS63222112A (ja) | 徐放性顆粒 | |
| JP2002370968A (ja) | 薬物含有徐放性顆粒およびそれを含む錠剤 | |
| KR100216624B1 (ko) | 경구투여용 서방성 제제 | |
| JPH06239756A (ja) | 制酸剤組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| G160 | Decision to publish patent application | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20051004 Year of fee payment: 13 |
|
| EXPY | Expiration of term |